📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial. (2024)

First Author: Kansiime S

Attributed to: A combination efficacy study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEP) – supplementary funding for MPLA-Liposomes funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1177/17407745241304721

PubMed Identifier: 39847674

Publication URI: http://europepmc.org/abstract/MED/39847674

Type: Journal Article/Review

Parent Publication: Clinical trials (London, England)

ISSN: 1740-7745